AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35201674 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg
Number of subjects: 668
Study 35201674 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (EM)
Number of subjects: 668
Study 35201674 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (CM)
Number of subjects: 668
Study 35201674 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 70 mg (overall population)
Number of subjects: 668
Study 35201674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 668
Study 33121984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 % HP-containing toothpaste (Toothwhole white)
Number of subjects: 49
Study 33121984 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 % HP-containing toothpaste (Vussen 7)
Number of subjects: 49
Study 33121984 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 % HP-containing toothpaste (Vussen 28)
Number of subjects: 49
Study 33121984 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 49
Study 35473653 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Internet-based cognitive-behavioral program (n=148)
Number of subjects: 293
Study 35473653 — intervention group
Group type: COMPARATOR
Intervention: Static Internet-based cognitive-behavioral program (n=145)
Number of subjects: 293
Study 35473653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (interactive and static)
Number of subjects: 293
Study 34544470 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 160 mg once daily
Number of subjects: 800
Study 34544470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 32660517 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg amoxicillin three times daily for 3 months
Number of subjects: 180
Study 32660517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 35514992 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccination (TIV)
Number of subjects: 260
Study 35514992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 32876469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM)
Number of subjects: 21
Study 32876469 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment maneuver (LRM) and PEEP
Number of subjects: 21
Study 35839450 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin followed by exercise
Number of subjects: 32
Study 35839450 — intervention group
Group type: COMPARATOR
Intervention: Exercise followed by desmopressin
Number of subjects: 32
Study 35839450 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 32
Study 32798112 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing group
Number of subjects: 81
Study 32798112 — intervention group
Group type: COMPARATOR
Intervention: conventional group
Number of subjects: 81
Study 33309467 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective and Sensory Psychotherapy Module (ASPM)
Number of subjects: 60
Study 33309467 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 32600481 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 163
Study 32600481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitochondrial-enhancing agents (CT)
Number of subjects: 163
Study 35718069 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable distal caps (group B)
Number of subjects: 400
Study 35718069 — intervention group
Group type: COMPARATOR
Intervention: Fixed distal caps (group A)
Number of subjects: 400
Study 616389365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabrasion (Group A)
Number of subjects: 90
Study 35377043 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training once a week for 6 weeks
Number of subjects: 200
Study 35377043 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 35377043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 200
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: No further axillary treatment recommended for underrepresented groups (premenopausal, HER2+/triple‐negative tumors, invasive lobular carcinoma)
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary discussion recommended for mastectomy patients
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for more data to change practice
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Accrual challenges to a clinical trial
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommendations for patients treated with NAC
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiation recommendation by radiation oncologists
Number of subjects: 94
Study 33720478 — intervention group
Group type: EXPERIMENTAL
Intervention: No further axillary treatment recommendation by surgeons
Number of subjects: 94
Study 35653615 — intervention group
Group type: EXPERIMENTAL
Intervention: IV golimumab 2 mg/kg at weeks 0 and 4, then every 8 weeks through week 52
Number of subjects: 112
Study 35653615 — intervention group
Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 12, crossover to IV golimumab at week 16
Number of subjects: 112
Study 34736721 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 575
Study 34736721 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 575
Study 33683919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 834
Study 33683919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 834
Study 33683919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 33052969 — intervention group
Group type: EXPERIMENTAL
Intervention: AR DSpecs (Augmented Reality Digital spectacles)
Number of subjects: 21
Study 35582897 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose gel followed by breastfeeding
Number of subjects: 629
Study 35582897 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) received only breastfeeding
Number of subjects: 629
Study 33043381 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide plus resistance band training
Number of subjects: 68
Study 33043381 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 68
Study 33176272 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 126
Study 33176272 — intervention group
Group type: COMPARATOR
Intervention: Cupping therapy
Number of subjects: 126
Study 35640544 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic polarizing cardioplegia (n=8)
Number of subjects: 13
Study 35640544 — intervention group
Group type: COMPARATOR
Intervention: Depolarizing cardioplegia (n=5)
Number of subjects: 13
Study 33371083 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic training (IKT)
Number of subjects: 60
Study 33371083 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stabilization training (CST)
Number of subjects: 60
Study 33371083 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 36214139 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (ACD 2.80 to 2.99 mm)
Number of subjects: 298
Study 36214139 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (ACD ≥ 3.00 mm)
Number of subjects: 298
Study 36214139 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 298
Study 33452923 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐mg dexamethasone (2 × 12‐mg)
Number of subjects: 60
Study 33452923 — intervention group
Group type: COMPARATOR
Intervention: 6‐mg dexamethasone (4 × 6‐mg)
Number of subjects: 60
Study 32476469 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature condition
Number of subjects: 18
Study 32476469 — intervention group
Group type: EXPERIMENTAL
Intervention: Built condition
Number of subjects: 18
Study 32476469 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 18
Study 35074820 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided web-based behavioural activation intervention (InterAKTIV)
Number of subjects: 128
Study 35074820 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 128
Study 33867499 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus supplementation (Ex + Suppl; n = 34)
Number of subjects: 70
Study 33867499 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control; n = 36)
Number of subjects: 70
Study 35172441 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neuromuscular electrical stimulation (NMES) for 20 minutes, 5 times a day, for 6 weeks before surgery.
Number of subjects: 40
Study 35172441 — intervention group
Group type: COMPARATOR
Intervention: Control group with no preoperative intervention, placed on a 6-week waiting list for surgery.
Number of subjects: 40
Study 33136047 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 5 weeks)
Number of subjects: 36
Study 33136047 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy radiation dose (1 fractioned dose of 2 Gy per day, 5 days per week, for 7 weeks)
Number of subjects: 36
Study 33136047 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Gy radiation dose
Number of subjects: 36
Study 33136047 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 Gy radiation dose
Number of subjects: 36
Study 33136047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no radiation)
Number of subjects: 36
Study 35182242 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFT)
Number of subjects: 121
Study 35182242 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training (CCT)
Number of subjects: 121
Study 35182242 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined NFT/CCT training
Number of subjects: 121
Study 35182242 — intervention group
Group type: COMPARATOR
Intervention: All training groups (NFT, CCT, NFT/CCT)
Number of subjects: 121
Study 34587236 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin and methylprednisolone (n = 245)
Number of subjects: 512
Study 34587236 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 267)
Number of subjects: 512
Study 32565482 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated arm ergometry training at moderate intensity (65%-75% HRpeak), three times per week for 12 weeks.
Number of subjects: 0
Study 32565482 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone (control group).
Number of subjects: 0
Study 36069629 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDHF with short‐segment plate and self‐locking stand‐alone cages (hybrid group)
Number of subjects: 60
Study 36069629 — intervention group
Group type: COMPARATOR
Intervention: ACDF with long‐segment plate (control group)
Number of subjects: 60
Study 34682785 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction (S) with 20 actuations
Number of subjects: 0
Study 34682785 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-suction (NS) with 15 actuations
Number of subjects: 0
Study 34682785 — intervention group
Group type: COMPARATOR
Intervention: Suction (S) with 15 actuations
Number of subjects: 0
Study 34682785 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary sampling with stylet slow-pull (CSSS) with 15 actuations
Number of subjects: 0
Study 35293068 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) 125 mg per day for 2 months
Number of subjects: 22
Study 35293068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 33303427 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling intervention (weave) delivered by trained family doctors; uptake rate: 49%.
Number of subjects: 272
Study 33303427 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control doctors with standard IPV information.
Number of subjects: 272
Study 35094742 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial assessment after self-harm
Number of subjects: 0
Study 35094742 — intervention group
Group type: COMPARATOR
Intervention: No assessment
Number of subjects: 0
Study 34516957 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 min of moderate aerobic exercise on a cycle ergometer
Number of subjects: 99
Study 34516957 — intervention group
Group type: COMPARATOR
Intervention: 30 min of simple lower body stretching routine (active control treatment)
Number of subjects: 99
Study 34516957 — intervention group
Group type: COMPARATOR
Intervention: Watching a popular sitcom (passive control treatment)
Number of subjects: 99
Study 35471470 — intervention group
Group type: EXPERIMENTAL
Intervention: SOR007 0.15%
Number of subjects: 23
Study 35471470 — intervention group
Group type: EXPERIMENTAL
Intervention: SOR007 1.0%
Number of subjects: 23
Study 35471470 — intervention group
Group type: EXPERIMENTAL
Intervention: SOR007 2.0%
Number of subjects: 23
Study 35471470 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 23
Study 35471470 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 23
Study 33800415 — intervention group
Group type: EXPERIMENTAL
Intervention: Active MBS
Number of subjects: 10
Study 33800415 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 10
Study 35582123 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 68
Study 35582123 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 68
Study 35582123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 33122899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (15-minute session)
Number of subjects: 21
Study 33122899 — intervention group
Group type: COMPARATOR
Intervention: Sham (15-minute session)
Number of subjects: 21
Study 34983040 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic to attenuate somatosensory inputs to the big toes
Number of subjects: 0
Study 34983040 — intervention group
Group type: COMPARATOR
Intervention: Sham anaesthetic (control group)
Number of subjects: 0
Study 33346477 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin at a dose of 1700 mg/day for 12 months
Number of subjects: 54
Study 33346477 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin at a dose of 1700 mg/day for 12 months, correction of vitamin D deficiency with cholecalciferol at a dose of 4000 IU/day for 6 months, then 2000 IU/day for another 6 months, and melatonin preparation at a dose of 3 mg/day for 6 months
Number of subjects: 54
Study 33346477 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 54
Study 33058901 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face inclusion
Number of subjects: 84
Study 33058901 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face exclusion
Number of subjects: 84
Study 33058901 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar inclusion
Number of subjects: 84
Study 33058901 — intervention group
Group type: COMPARATOR
Intervention: Avatar exclusion
Number of subjects: 84
Study 33058901 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer VR-agent inclusion
Number of subjects: 84
Study 33058901 — intervention group
Group type: COMPARATOR
Intervention: Computer VR-agent exclusion
Number of subjects: 84
Study 32461510 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensodyne toothpaste
Number of subjects: 50
Study 32461510 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest toothpaste
Number of subjects: 50
Study 32461510 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate toothpaste
Number of subjects: 50
Study 32461510 — intervention group
Group type: COMPARATOR
Intervention: Dental desensitizer
Number of subjects: 50
Study 36241996 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + E-TRAIN
Number of subjects: 138
Study 36241996 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 138
Study 32507638 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative physiotherapy education (POPE) combined with postoperative physiotherapy (POP)
Number of subjects: 21
Study 32507638 — intervention group
Group type: COMPARATOR
Intervention: Postoperative physiotherapy (POP) only
Number of subjects: 21
Study 32754966 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination (offered to women born in 1993)
Number of subjects: 35799
Study 32754966 — intervention group
Group type: COMPARATOR
Intervention: No HPV vaccination (women born in 1983)
Number of subjects: 35799
Study 35338628 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention focusing on preventing childhood unintentional injuries.
Number of subjects: 0
Study 35338628 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 33309237 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Economic Adherence for Teens (BEAT) intervention, which includes a text messaging system and a graphical user interface
Number of subjects: 12
Study 35730719 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic escitalopram oxalate (n = 60)
Number of subjects: 125
Study 35730719 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 65)
Number of subjects: 125
Study 33999179 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Number of subjects: 4769
Study 33999179 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 4769
Study 32644110 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA (ctDNA) positive
Number of subjects: 196
Study 32644110 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA positive and CTC positive
Number of subjects: 196
Study 35039194 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 lot 1
Number of subjects: 2340
Study 35039194 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 lot 2
Number of subjects: 2340
Study 35039194 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 lot 3
Number of subjects: 2340
Study 35039194 — intervention group
Group type: COMPARATOR
Intervention: V114 combined lots
Number of subjects: 2340
Study 35039194 — intervention group
Group type: COMPARATOR
Intervention: V114
Number of subjects: 2340
Study 34465201 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral fluoxetine once daily for 6 months
Number of subjects: 1500
Study 34465201 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 6 months
Number of subjects: 1500
Study 35262918 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral upper limb training
Number of subjects: 32
Study 35262918 — intervention group
Group type: COMPARATOR
Intervention: Bilateral upper limb training
Number of subjects: 32
Study 32651467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1) administered every two weeks for four cycles (two cycles prior to first HDR, two cycles prior to second HDR) combined with androgen deprivation therapy (ADT) and high-dose-rate (HDR) brachytherapy.
Number of subjects: 6
Study 32651467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (anti-PD-1)
Number of subjects: 6
Study 35476592 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Approach to Reintegrate clients with multiple problems (CARm)
Number of subjects: 207
Study 35476592 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 207
Study 32911988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (600 IU/day plus 50,000 IU/week)
Number of subjects: 59
Study 32911988 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin D (600 IU/day plus placebo weekly)
Number of subjects: 59
Study 32303164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 32303164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 0
Study 32303164 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 0
Study 32303164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 36121247 — intervention group
Group type: EXPERIMENTAL
Intervention: PASCAL system
Number of subjects: 180
Study 36121247 — intervention group
Group type: COMPARATOR
Intervention: MitraClip system
Number of subjects: 180
Study 34513765 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS and cognitive training (20 min/session, total 20 sessions, for 12 weeks)
Number of subjects: 13
Study 34513765 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS and cognitive training
Number of subjects: 13
Study 32621898 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece intraocular lens (IOL)
Number of subjects: 1400
Study 32621898 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-piece intraocular lens (IOL)
Number of subjects: 1400
Study 32621898 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule tension ring (in PEX group)
Number of subjects: 1400
Study 32621898 — intervention group
Group type: EXPERIMENTAL
Intervention: No capsule tension ring (in PEX group)
Number of subjects: 1400
Study 32621898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEX)
Number of subjects: 1400
Study 35530957 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical laparo-gastroscopic esophagectomy (LGE)
Number of subjects: 0
Study 35530957 — intervention group
Group type: COMPARATOR
Intervention: Radical laparo-thoracoscopic esophagectomy (LTE)
Number of subjects: 0
Study 32681922 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor stool (FMT)
Number of subjects: 62
Study 32681922 — intervention group
Group type: COMPARATOR
Intervention: Placebo (autologous stool)
Number of subjects: 62
Study 35879537 — intervention group
Group type: EXPERIMENTAL
Intervention: OFRA intervention (mobility and falls prevention classes, examination of bone health, consultation on safety in the home)
Number of subjects: 9408
Study 35879537 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9408
Study 32795330 — intervention group
Group type: EXPERIMENTAL
Intervention: Auxora
Number of subjects: 30